Skip to main content

Table 2 Clinical data and co-medication before and after treatment

From: Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series

Patient Initial UHDRS motor score Second UHDRS motor score Valproic acid (mg/day) Valproic acid serum level (μg/ml) Mood stabiliza-tion Improve-ment of mobility and manual dexterity Changes in co-medication in mg
Case 1 80 72 900 30 +++ + T100 CBZ900 MEL37.5 TE, LO CL25
Case 2 65 33 1200 87 - +++ R
Case 3* 79 61 1800 59 + + T100 CL44 CLO0.5 LEV1000 TE CBZ400
Case 3* 84 74 2700 43 ++ ++ T300 TE25 CLO0.5 CL CBZ400
Case 4 56 56 300 (ND) - - T, TE, LO, OX, HAL
Case 5 72 66 900 73 ++ + T, HAL
Case 6 74 60 1050 43 +++ ++ T150 TE25 S200 Q
Case 7 57 50 1950 84 + +++ T300 LO1.5
Case 8 91 70 1350 56 ++ ++ T50 LO, Q, MEL
  1. Clinical data and co-medication before (initial UHDRS motor score) and after (second UHDRS motor score) treatment with valproic acid. ND = no data; Intensity: - = no, + = mild, ++ = moderate, +++ = very good. Medication: T = Tiaprid, TE = Tetrabenazine, CBZ = Carbamazepine, CL = Clozapine, CLO = Clonazepam, MEL = Melperone, LO = Lorazepam, R = Rilutek, LEV = Levetiracetam, OX = Oxazepam, HAL = Haloperidol, S = Sulpride, Q = Quetiapin. Signs: Increase = , decrease = no change = . One patient (*) was treated twice with an increased dose of valproic acid within a 4 year period, see text.